Bullish Alert on Tiziana Life Sciences Ltd (NASDAQ: TLSA) – Set For 85% Surge Amidst Alzheimer’s Drug Boom💊
Published: Fri, 02/14/25
Updated: Fri, 02/14/25
Get the Full Story - Breaking News Released! Download our Mobile App📱
SPONSORED
.
Bullish Alert on Tiziana Life Sciences Ltd (NASDAQ: TLSA) – Set For 85% Surge Amidst Alzheimer’s Drug Boom💊
Tiziana Life Sciences Ltd.
(NASDAQ: $TLSA)
===========================
Alert Price - $0.7489 per share
Market Cap - $80.72M
Avg. Volume - $334,399
Members,
We're thrilled to unveil our latest pick, Tiziana Life Sciences Ltd (NASDAQ: TLSA)—a biotech company making groundbreaking strides in immunology and oncology. With a pipeline of cutting-edge therapies targeting some of the most challenging diseases, NASDAQ: TLSA could be on
the verge of a game-changing breakout.
We believe NASDAQ: TLSA could be boomer trade with a 85% surge in sight, offering a compelling short-term setup while holding long-term potential as a major player in the biotech space.
Watch Recent milestone here:
Technical Overview
Tiziana Life Sciences Ltd (NASDAQ: TLSA) shares are up 1.35% in Friday's premarket trading. The stock’s Relative Strength Index (RSI) stands at 52.77, which, despite the recent decline, suggests that bullish momentum is building. The RSI is neither overbought nor oversold, indicating a healthy consolidation phase before a potential upward move.
For (NASDAQ: TLSA) shares, the immediate support lies in the 78.6% Fibonacci retracement point a level not so far from the current price will serve as a springboard towards greater highs with eyes set on 85% gain as confirmed by the falling wedge
pattern.
Similarly, a breakout above the 38.2% Fibonacci level could pave the way for the anticipated 85% surge on the horizon without testing the support point aforementioned above.
Tiziana Life Sciences Ltd (NASDAQ: TLSA) Chart pattern is flashing a classic double-bottom formation, a high-probability
reversal pattern that often precedes explosive upward moves. The stock has established a strong base around $0.63, aligning with its one-month low, reinforcing a solid support level.
Adding to the bullish outlook, NASDAQ: TLSA's Relative
Strength Index (RSI) currently sits at 50.89, indicating that the stock is neither overbought nor oversold—a prime zone where momentum can build up for an aggressive push higher. Moreover, NASDAQ: TLSA is trading below its moving average (MA), signaling that there’s significant room for upside. As the stock reclaims key levels, it could trigger an influx of buyers, further accelerating the rally.
Given these technical alignments, NASDAQ: TLSA could be setting up for an 85% surge, offering
traders a strategic opportunity to capitalize on its momentum before the breakout fully unfolds.
About Tiziana Life Sciences (NASDAQ: TLSA)
Tiziana Life
Sciences Ltd. (NASDAQ: TLSA) is a United Kingdom-based biotechnology company, founded in 2013, that focuses on groundbreaking treatments in immunology and oncology. The company went public on March 24, 2000, and operates within the healthcare sector, specializing in cutting-edge biotech advancements. Despite having a lean team of just nine employees, Tiziana is making significant strides under the leadership of CEO Ivor Elrifi.
Its lead product candidate, Foralumab (TZLS-401), is the first and only fully human anti-CD3 monoclonal antibody, showing immense potential in treating multiple sclerosis, Crohn’s disease, ulcerative colitis, and other inflammatory conditions.
Headquartered in London, Tiziana Life Sciences Ltd. continues to push the boundaries of biotech innovation, positioning itself as a key player in the fight against autoimmune diseases and cancer.
The segment highlighted the experiences of the first patient dosed in the company’s expanded access program for moderate Alzheimer’s disease.
In the segment, Joe and his Wife, Karen, shared their journey and shed light on the hope that innovative therapies like Foralumab offer for individuals battling moderate Alzheimer’s, a condition that currently has no cure and limited treatment options.
Dr.
Howard Weiner, Co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham healthcare system commented:
“Foralumab, administered via a novel
intranasal delivery method, aims to target immune system dysregulation associated with Alzheimer's disease, potentially slowing disease progression and improving cognitive function. The recent coverage in the News underscores the growing recognition of Foralumab's promise in the field of neurodegenerative diseases.”
CEO of Tiziana Life Sciences, Ivor Elrifi Commented:
"We are swiftly advancing towards expanding our nasal foralumab technology from successful applications in neurologic diseases like secondary progressive multiple sclerosis to now encompass spinal cord
injury. This underscores our commitment to pioneering treatments that address significant unmet medical needs."
Dr. Howard Weiner, Chairman of Tiziana’s Scientific Advisory Board and co-director of the Ann Romney Center for
Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham healthcare system opined:
"Our pre-clinical findings underscore the pivotal role of nasal anti-CD3 in modulating microglial inflammation associated with spinal cord injury"
Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, further commented:
“Treatment with nasal anti-CD3
not only dampened microglial activation but also led to marked improvements in motor function among the injured models. These results hold promise for a transformative therapeutic approach in SCI.”
Announces its intention not to engage in a capital raising activities for the immediate future.
Following on from its news of the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab, the Company has decided not to engage in a capital raising activities for the immediate future.
Tiziana’s management team remains
committed to delivering value to its shareholders and advancing its innovative drug candidates through clinical trials and regulatory processes.
Dr. Tanuja Chitnis, M.D., Principal Investigator and Professor of Neurology at Harvard Medical School and senior neurologist at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System commented:
“We
are excited to announce this breakthrough in understanding how nasal foralumab induces immune modulation in Secondary Progressive MS patients,”
These findings highlight the potential of nasal foralumab in modulating critical immune pathways and offer new insights into its
clinical effects. This discovery represents a pivotal step toward personalized treatment strategies for MS. We look forward to submitting these data to a peer reviewed journal.”
Dr. Howard Weiner, Chairman of Tiziana’s Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at
Brigham stated that:
“The observed clinical stabilization and microglial PET findings are supported by these new biomarker discoveries, providing compelling evidence of nasal foralumab's biological effects,”
“The
identification of these biomarkers not only strengthens our understanding of the treatment’s mechanism but also establishes a framework for monitoring its efficacy in future trials and may establish a framework for monitoring a patient’s response to foralumab treatment.”
Why Tiziana Life
Sciences (NASDAQ: TLSA) Stands Out
Tiziana Life Sciences (TLSA) is revolutionizing immunotherapy with cutting-edge treatments aimed at neurodegenerative and neuroinflammatory diseases. Unlike conventional biotech companies, Tiziana is taking a next-generation approach to drug development, focusing on precision immunotherapies that target the root causes of chronic conditions rather than just
alleviating symptoms.
At the heart of its innovation is Foralumab (TZLS-401), a fully human anti-CD3 monoclonal antibody that is currently the only one of its kind under clinical development. This breakthrough therapy is being developed to treat Non-Active Secondary Progressive Multiple Sclerosis (SPMS), Alzheimer’s disease, and other
central nervous system (CNS) disorders. By modulating the immune response rather than suppressing it, Foralumab has the potential to significantly reduce inflammation, which is a major driver of neurodegenerative diseases.
This differentiates it from conventional Alzheimer’s treatments, which often focus on reducing amyloid plaques
without addressing the immune system’s role in disease progression.
Beyond neuroinflammatory conditions, Tiziana is expanding its impact in oncology. The company has filed a patent application for the use of Foralumab to enhance CAR-T therapy, a groundbreaking cancer treatment that has already transformed the landscape of
personalized medicine. By improving CAR-T cell expansion and survival, Tiziana could increase the effectiveness of these therapies, making cancer treatments more durable and accessible to a broader patient base.
What sets Tiziana apart is not just its scientific breakthroughs, but also its strategic and highly efficient business model. Operating with a lean and virtual research and development approach, the company collaborates with expert teams worldwide, ensuring that resources are
maximized and focused on bringing innovative therapies to market. This cost-effective structure allows Tiziana to operate with a small yet highly specialized team, giving it an edge over larger biotech firms weighed down by bureaucracy and excessive spending.
Under the leadership of CEO Ivor Elrifi, Tiziana Life Sciences has positioned itself as a high-growth biotech disruptor with the potential to redefine how immune-based diseases are treated. With a strong research pipeline, strategic innovation in immunotherapy, and a commitment to delivering life-changing treatments, TLSA is not
just another biotech stock—it’s a pioneer in the next era of medical breakthroughs.
The Evolution of Neurodegenerative Diseases: Understanding SPMS, Alzheimer’s, and ALS
Neurodegenerative diseases like Alzheimer’s, Non-Active Secondary Progressive Multiple Sclerosis (SPMS), and Amyotrophic Lateral Sclerosis (ALS) have challenged the medical community for decades. Since Dr. Alois Alzheimer first identified Alzheimer’s disease in 1906, researchers have worked tirelessly to understand the complexities of these disorders, uncovering key pathological markers such as amyloid plaques and
tau tangles. Similarly, SPMS and ALS, both progressive in nature, have long lacked effective treatments, leaving millions of patients with limited options.
Despite groundbreaking discoveries in neuroscience, the search for a cure or highly effective therapy has largely remained elusive. Over the years, the industry has seen
major advancements in disease-modifying treatments, with researchers exploring monoclonal antibodies, immunotherapies, and cellular-based approaches to slow disease progression. However, many solutions have failed to provide long-term efficacy due to adverse immune responses or limited bioavailability.
Tiziana Life Sciences
(NASDAQ: TLSA) is pioneering a new era of next-generation immunotherapies, focusing on Foralumab (TZLS-401)—a fully human anti-CD3 monoclonal antibody designed to treat Alzheimer’s, Non-Active SPMS, and other CNS-related conditions. What makes Foralumab particularly unique is its ability to modulate the immune system without triggering severe adverse effects, a breakthrough that could redefine treatment paradigms.
Tiziana’s cutting-edge research and innovative approach have positioned
it at the forefront of the neurodegenerative battle. With a patent application already submitted for improving CAR-T therapy for cancer and other diseases, the company isn’t just making progress—it’s leading the charge. As the demand for effective therapies in this space continues to grow, TLSA could be the biotech stock to watch in 2024 and beyond.
Tiziana
Life Sciences (NASDAQ: TLSA) - Key Metrics
Total Valuation - Market Cap: $80.72M - Enterprise Value $79.77M
Tiziana Life Sciences (NASDAQ: TLSA) has a market cap or net worth of $80.72 million
as of February 14, 2025. Its market cap has increased by a staggering 46.32% in one year.
Important Dates - Next Earnings Date: February 25, 2025 (Before Market Open)
ThinkEquity Firm analyst Ashok Kumarhas a "strong buy" ratings on TLSA stock with a $4 price target and a +440.54% price uptick.
Why Now is
the Time to Consider Tiziana Life Sciences (NASDAQ: TLSA)
Tiziana Life Sciences (TLSA) presents a compelling opportunity at its current levels, backed by strong technical indicators and groundbreaking advancements in neurodegenerative disease treatments. The stock is showing a double bottom formation near $0.63, a classic bullish reversal pattern that historically precedes major upward
moves.
With the RSI at 50.89, TLSA is neither overbought nor oversold, signaling ample room for an upside breakout. Additionally, it's trading below its moving averages, a setup that often allows for high-percentage gains when momentum kicks in—setting the stage for a potential 85% surge.
Beyond technicals, the company is spearheading the next generation of immunotherapies, with Foralumab (TZLS-401) being the only fully human anti-CD3 monoclonal antibody under development.
Its potential to revolutionize treatment for Alzheimer’s, Multiple Sclerosis, and ALS makes TLSA a standout player in the biotech sector. As the demand for effective therapies skyrockets, this stock could be primed for significant revaluation.
With institutional interest growing, and a breakthrough in a
multi-billion-dollar industry, TLSA is an opportunistic trade with a long-term growth narrative—a rare biotech play that could deliver exponential returns.
Don’t miss out—Tiziana Life Sciences (NASDAQ: TLSA) is about to explode in value, and this is your chance to get in early!
As always, we encourage you to conduct your own research and consider how Tiziana Life Sciences (NASDAQ: TLSA) fits into your broader investment strategy.
This newsletter is a Paid Advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by DEXWireNews LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to DEXWireNews LLC.
You are reading this
newsletter because you have subscribed via our opt-In signup form on our website. If you have been subscribed by accident, then you may unsubscribe by clicking the link below.
By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or
licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research
and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our
website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be
based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here: We do NOT own shares of any of the companies mentioned herewithin, nor intend to buy any in the future.
You should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at http://www.sec.gov and the Financial Industry Regulatory Authority (the "FINRA") at http://www.FINRA.org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud
at https://www.sec.gov/reportspubs/investor-publications/investorpubscyberfraudhtm.html, as well as related information published on how to invest carefully. You are responsible for verifying all claims and conducting your own
due diligence. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or
information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory
service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company.
Our business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars electronically via bank wire by One
Eyed Jack Enterprises LLC for an advertising / marketing campaign for Tiziana Life Sciences Ltd. (NASDAQ: $TLSA) beginning on 2/13/2025 and ending on 2/20/2025. DEXWireNews may receive additional campaigns in the future by One Eyed Jack Enterprises LLC to distribute media for Tiziana Life Sciences Ltd. (NASDAQ: $TLSA).
Any
compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely
for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may
contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not
been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, we often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are
double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change
at any time without notice.
Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at
different times that are minutes, hours, days or even weeks apart.
How is a potential investor impacted if they receive the Information later than other investors? If the trading volume and price of a Profile Issuer’s securities increases after the Information is provided to an earlier group of investors, then subsequent investors will pay inflated prices for any securities of the Profiled Issuers that they purchase. This will likely result in the Profiled Issuers having trading losses.
